Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach $3.1 billion in total value, is expected to close in the early part of 2025.
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Artificial intelligence could be used to prescribe medications to patients — if a new bill makes its way through Congress ...
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback